Multiple Sclerosis Clinical Trial
A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstroâ„¢ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis
Summary
This was a multicenter, open-label, randomized, crossover trial in subjects with MS who were already taking a stable dose of baclofen (up to 80 mg/day) for spasticity. The trial was designed to assess subject preference for Kemstro or conventional baclofen. At Visit 1, subjects were screened, and if qualified, were randomly assigned to one of two following treatment sequences: Kemstro/conventional baclofen or conventional baclofen/Kemstro.
Eligibility Criteria
Inclusion Criteria:
stable dose of baclofen
Exclusion Criteria:
not stable dosing
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Milwaukee Wisconsin, , United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.